Glaxo Smith Kline in conjunction with Vir Biotechnology funded by CEPI, Bill Gates, and The Wellcome Trust has been granted FDA authorization use for a monoclonal antibody drug administered via IV injection for SARS-Cov. The drug is only in Phase 2 Trials, which included 868 patients, 63% of whom were Hispanic and 7% Black. They did not provide the race of the remaining 30%. The claim is that the drug is 85% effective in reducing hospitalization or death in those with mild to moderate SARS-Cov who are at high risk. They don’t define what makes someone ‘high risk’. Is it because they are Hispanic? Or is it because they are 85 years old?
Glaxo defines primary efficacy endpoint as “the proportion of patients who have progression of COVID-19 as defined by the need for hospitalization for greater than 24 hours for acute management of illness or death.” Therefore if a person did not die, the drug was considered effective!
Given that the trials are scarce to none, potential adverse effects should be duly noted:
Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of Sotrovimab. These reactions may be severe or life threatening. Including: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia, chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions, dizziness and diaphoresis.
In addition, many of these reactions have been observed more than 24 hours after the injection requiring hospitalization.
The entire Phase 2 Trial time frame observed was 29 days.
The Wellcome Trust is chaired by Eliza Manningham Buller, a former intelligence officer with MI5. She was a teacher of English before being recruited to work for the UK Security Service specializing in counter-terrorism and espionage… Interesting transition. The NGO nontaxable Wellcome Trust invests a portion of its 26billion Euro Endowment in Pharmaceutical companies that it supports financially – such as Glaxo Smith Kline.
The Conflict of Interest is so verbose it is astounding!
GSK has attested that further clinical trials for their experimental drug, Sotrovimab, will begin sometime during the second quarter of 2021 having only entered into the Vir Biotechnology collaboration this past April – 2 months ago. In addition, there are caveats about who may receive the drug including anyone needing oxygen and possibly pregnant women…
If you thought the SARS-CoVid vaccine was using the global population as their Phase 4 Trial – Sotrovimab MRna has only passed Phase 2 and the FDA’s authorization is proof positive we are the Guinea Pigs for Phase 3!